image

Current Clinical Trials:

LGMD 2C :

ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5 Status : NOT YET RECRUITING Sponsor: Atamyo Therapeutics

LGMD 2D:

A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D) Status : COMPLETED Sponsor: Sarepta Therapeutics, Inc.

Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D) Status : COMPLETED Sponsor: Nationwide Children's Hospital There are no clinical trials available for LGMD2D patients at this time.

LGMD 2E :

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency) Status : ACTIVE, NOT RECRUITING Sponsor: Sarepta Therapeutics, Inc.

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/​R4 (Beta-Sarcoglycan [β-SG] Deficiency) Status : ACTIVE, NOT RECRUITING Sponsor: Sarepta Therapeutics, Inc.

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/​R4 (EMERGENE) Status : RECRUITING Sponsor: Sarepta Therapeutics, Inc.

Current Research :

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice Status : RECRUITING Sponsor: Sarepta Therapeutics, Inc.

Long-Term Development of Muscular Dystrophy Outcome Assessments (GRASP-01-005) Status : ACTIVE, NOT RECRUITING Sponsor: Virginia Commonwealth University

Natural History Study in Patients With LGMDR5/​2c Status : NOT YET RECRUITING Sponsor: Atamyo Therapeutics

Clinical Determinants of Disease Progression in Patients With Limb Girdle Muscular Distrophy Type 2E (NeuroLGMD2E) Status : COMPLETED Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinicos

Limb Girdle Muscular Dystrophy Type 2E Recruitment Study Status : RECRUITING Sponsor: Nationwide Children's Hospital

Natural History of Limb Girdle Muscular Dystrophy Type 2A and Type 2E Status : RECRUITING Sponsor: Linda Pax Lowes

Current Research Progress

2C

Discovery and Research
Preclinical Development
Investigational New Drug (IND) Application
Clinical Trials - Phase I
Clinical Trials - Phase II
Clinical Trials - Phase III
New Drug Application (NDA) Submission
Regulatory Review: FDA or EMA

2D

Discovery and Research
Preclinical Development
Investigational New Drug (IND) Application
Clinical Trials - Phase I
Clinical Trials - Phase II
Clinical Trials - Phase III
New Drug Application (NDA) Submission
Regulatory Review: FDA or EMA

2E

Discovery and Research
Preclinical Development
Investigational New Drug (IND) Application
Clinical Trials - Phase I
Clinical Trials - Phase II
Clinical Trials - Phase III
New Drug Application (NDA) Submission
Regulatory Review: FDA or EMA

2F

Discovery and Research
Preclinical Development
Investigational New Drug (IND) Application
Clinical Trials - Phase I
Clinical Trials - Phase II
Clinical Trials - Phase III
New Drug Application (NDA) Submission
Regulatory Review: FDA or EMA

Cost of Development

The cost of LGMD research extends beyond finances, reflecting a global commitment of time and effort. Financial requirements at each stage provide a roadmap for progress towards treatments and cures.

Drug Development Program
Stage 1
Characterize Mutation
$0
Stage 2
Prototype & Optimise
$500,000
Stage 3
Test efficacy

$500,000
Stage 4
Manufacture and Test Safety

$2,500,000
Stage 5
Clinical Trial
$5,000,000